Showing results (21-30 of 62) with videos related to
Sort By:
Pageof 7
Journal of Clinical Laboratory Analysis|May 27, 2016
Comparison of Screening Dilution and Automated Reading for Antinuclear Antibody Detection on HEP2 Cells in the Monitoring of Connective Tissue DiseasesAnne E Depincé-Berger, Amelie Moreau, Virginie Bossy, et al.Proceedings of the National Academy of Sciences of the United States of America|August 31, 2004
Gene-based vaccines and immunotherapeuticsMargaret Liu, Bruce Acres, Jean-Marc Balloul, et al.Expert Review of Vaccines|October 12, 2013
Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriageElisabeth Botelho-Nevers, Paul Verhoeven, Stephane Paul, et al.European Eating Disorders Review : the Journal of the Eating Disorders Association|June 25, 2022
Association of gut-specific non-inflammatory T lymphocytes with chronic anorexia nervosa and constitutional thinnessTristan Gabriel, Catherine Massoubre, Mouna Hanachi, et al.Journal of Crohn'S & Colitis|September 25, 2019
Therapeutic Drug Monitoring of Biologics During Induction to Prevent Primary Non-ResponseMiles P Sparrow, Konstantinos Papamichael, Mark G Ward, et al.Molecular Pharmaceutics|July 26, 2016
Zinc-Stabilized Chitosan-Chondroitin Sulfate Nanocomplexes for HIV-1 Infection Inhibition ApplicationDanjun Wu, Agathe Ensinas, Bernard Verrier, et al.Journal of Materials Chemistry. B|April 9, 2020
Zinc-stabilized colloidal polyelectrolyte complexes of chitosan/hyaluronan: a tool for the inhibition of HIV-1 infectionDanjun Wu, Agathe Ensinas, Bernard Verrier, et al.Expert Review of Gastroenterology & Hepatology|October 9, 2024
Therapeutic drug monitoring in inflammatory bowel disease: recent developmentsXavier Roblin, Robert D Little, Nicolas Mathieu, et al.Digestive Diseases and Sciences|September 16, 2020
No Difference of Adalimumab Pharmacokinetics When Dosed at 40 mg Every Week or 80 mg Every Other Week in IBD Patients in Clinical Remission After Adalimumab Dose IntensificationStephane Paul, Nicolas Williet, Stéphane Nancey, et al.Current Drug Targets|September 1, 2014
Pharmacokinetics in IBD: ready for prime time?Xavier Roblin, Melanie Rinaudo, Miles Peter Sparrow, et al.Pageof 7